Biotech Co.*

Pharma Co.

Type/Product Area

Terms/Details (Date)


F. Hoffmann-La Roche Ltd.(Switzerland)

Agreement to produce fully human monoclonal antibodies against an undisclosed oncology target

In exchange for screening and antibody engineering work, Affitech will receive an unspecified amount of research fees,  milestone payments and royalties (5/7)




Agreement to examine the feasibility of developing a transdermal patch product that delivers certain macro-molecular carbohydrates to  treat coagulation disorders

The agreement allows the companies an option to enter a broader licensing arrangement for clinical development and commercialization (5/3)


Antisoma plc

Novartis AG (Switzerland)

Exclusive, global licensing agreement for the vascular disruptin agent AS1404

Antisoma will receive $100M in near-term payments, and is eligible for total up-front and milestone payments of up to $890M, contingent on successful marketing of the product in multiple indications and the achievement of certain sales; Antisoma also is entitled to royalties and has an option to co-commercialize in the U.S. (4/19)


ArQule Inc.

Kyowa Hakko Kogyo Co. Ltd. (Japan)

Partnership for the cancer agent ARQ 197 in Japan, China, South Korea and Taiwan

ArQule gets $30M up front in the deal and is entitled to up to $93M in development milestone payments, as well as undisclosed sales milestone payments and a double- digit, tiered royalty on any resulting sales (4/27)


and Taconic
Farms Inc.*

CGI Pharmaceuticals Inc.

Agreement for worldwide rights to the ASKA technology from CGI

Artemis and Taconic are assigned the entire portfolio of ASKA intellectual property rights (5/2)



GlaxoSmithKline plc (UK)

Non-exclusive, worldwide license agreement to Astex's cytochrome P450 intellectual property

Astex will receive an up-front fee (4/24)



Schering-Plough Corp.

Partnership for a preclinical antibody program, AV-299, which is designed to bind to and inhibit the hepatocyte growth factor/scatter factor

Schering-Plough will fund all research and development, and will pay AVEO $7.5M up front, plus a $10M equity investment; commercial and development milestones could exceed $460M; AVEO also would be eligible for royalties, and it holds a co- promotion option in the U.S. (4/4)


Axxam SpA*

PerkinElmer Inc.

Agreement under which PE will become the exclusive provider of Axxam's Photina photoprotein technology to the drug discovery market

Terms provide for a formal R&D program for additional Photina GPCR and ion channel cell lines for use in high-throughput screening and compound profiling (5/22)



Merial Ltd. (joint venture of Merck & Co. Inc. and Sanofi- Aventis; France)

Collaboration to develop animal health products using Biolex's LEX System

The goal is to provide Merial with vaccine antigens; Biolex is entitled to research and development support and milestones; Merial may exercise an option regarding a worldwide license (5/1)


Pharma Corp.
(Canada; CRME)

Eli Lilly & Co.

Exclusive, in-licensing agreement for worldwide rights to LY458202 (GED-aPC) for all indications

Cardiome intends to develop the drug in cardiogenic shock and anticipates beginning Phase I studies in the second half of 2007; terms include a $20M up- front pay- ment to Lilly, plus development milestones not to exceed $40M, and royalty payments based on sales (4/30)


Cellectis SA
(France; PARIS:

GlaxoSmithKline plc (UK)

Worldwide, nonexclusive sublicense agreement to a patent family relating to a  process for the specific replacement or insertion of a gene in a receiver  genome by homologous recombination

The technology is used to substitute,  delete or add genetic sequences at a chosen location in a genome (5/16)**


Clinical Data

Roche Diagnostics (subsidiary of Roche Holding AG; Switzerland)

Co-marketing agreement in support of the installation  of a 454 Genome Sequencer FLX System in one of Clinical Data's European facilities

The technology will be offered on a fee- for- ervice basis, with applications ranging from whole genome sequencing to genomewide expression profiling (3/29)


Codexis Inc.*

Merck & Co. Inc.

Three-year, nonexclusive licensing agreement to the Codex Biocatalyst Panels

Merck is the first subscriber of the product, which consists of sets of diagnostic enzyme panels designed to identify optimizable biocatalytic process solutions for chemically challenging manufacturing issues (4/3)


Group Inc.

Merck & Co. Inc.

Licensing deal that gives Merck rights to VaxImmune, an adjuvant technology, for  use in developing vaccines for infectious diseases and Alzheimer's

Coley will get $4M up front and up to $33M in milestones, as well as royalties on any product sales; Merck holds nonexclusive rights for certain infectious disease fields and Alzheimer's disease, and holds an option to add additional disease areas (4/12)


Cytos AG

Novartis AG (Switzerland)

Partnership for CYT002- NicQb, a therapeutic vaccine for nicotine addiction

Novartis received worldwide rights to the drug, which has completed Phase II trials; Cytos gets CHF35M (US$29M) up front, with CHF565M more tied to certain milestones; it also is eligible for royalties (4/25)


EpiStem plc

AstraZeneca plc (UK)

Agreement to use EpiStem's plucked hair biomarker  technology to help guide preclinical and clinical development of cancer drugs

Terms of the deal were not disclosed (5/22)


of Danisco A/S;

Pfizer Inc.

Nonexclusive licensing agreement for technology that enhances the expression level of secreted polypeptides  in microorganisms for use in the development of protein therapeutics

The technology is designed to improve processes for protein production, which in turn might reduce development costs for protein-based drugs (4/2)



Servier (France)

Collaboration to connect results from high-throughput microarray experiments to  qPCR platforms from different vendors, including Servier reagent datasets

GenomeQuest retained the right to  commercialize the software and know-how (5/1)


Helix BioMedix

DermaVentures  LLC

Agreement to provide technology and services to  allow DermaVentures to use Helix's peptide technologies, and to  manage day-to-day operations

DermaVentures will take an equity position in Helix BioMedix (4/23)


InNexus Biotechnology Inc. (Canada; CDNX:IXS)

Royalty Pharma

Agreement for a royalty interest in up to two cancer products based on InNexus' Dynamic Cross Linking antibody enhancement technology

Royalty Pharma will buy the first royalty interest for $2M and will hold an option to purchase a royalty interest in a second product for an additional $2M; it also will make a $1M equity investment in InNexus (4/26)


Inno Biologics
Sdn. Bhd.*

Boehringer Ingelheim GmbH (Germany)

10-year cooperation agreement whereby Inno clients will have access to BI's manufacturing technology platform

The platform will be used for Phase I and Phase II biopharmaceutical products produced by mammalian cell culture (5/10)



Bristol-Myers Squibb Co.

Agreement for the Phase II low- ensity lipoproteincholesterol-lowering drug, ISIS 301012

Bristol-Myers gets an exclusive license to the PCSK9 program, as well as $15M up front, at least $9M in research funding over three years, up to $168M in milestones and royalties (5/9)



Novartis AG (Switzerland)

Non-exclusive, licensing agreement for KaloBios Humaneering method for humanizing antibodies

Terms were not disclosed (4/24)



Thornton & Ross Ltd. (UK)

Exclusive North American rights agreement to  develop and commercialize  two product candidates from Thornton & Ross

The two candidates are Altoderm for atopic dermatitis or eczema and Altolyn for mastocytosis (4/4)


Medarex Inc.

Organon NV (the Netherlands)

Joint development and commercialization deal for  fully human monoclonal antibody against an undisclosed target in the areas of cancer and auto- immune disease

It is a 50-50 partnership; both firms will share responsibilities and revenues (5/16)



Sanofi Pasteur (France)

Licensing agreement for MedImmune's reverse- genetics property

The license will support the development and construction of new vaccine strains for influenza vaccines; MedImmune will receive an up-front payment and could receive royalties on certain vaccine stockpiles or product sales (3/29)


Discovery Inc.*

Pfizer Inc.

Deal for Melior to apply its indications discovery platform to Pfizer's compounds

The theraTRACE platform entails multi- plexed in vivo assays designed to discover new therapeutics indications for existing pharmaceutical compounds (4/9)


Micromet Inc.

Nycomed A/S (Denmark)

Development deal for the preclinical MT203 program for rheumatoid arthritis, multiple sclerosis, psoriasis, asthma and chronic obstructive pulmonary disease

Micromet will receive reimbursements and  milestone payments, as well as royalties on sales; it is responsible for preclinical work, while Nycomed will cover clinical trials and worldwide commercialization (5/24)



Eisai Co. Ltd. (Japan)

Non-exclusive, licensing agreement for Fa2N-4 immortalized human  hepatocyte cells and MFE culture media

Eisai will use the technology for drug discovery/ADMETOX applications; terms were not disclosed (4/24)



ALZA Corp. (unit of Johnson & Johnson)

Agreement for U.S. rights to OROS Hydromorphone

Neuromed paid $30M up front and will pay milestones and royalties for the pain drug (4/24)



Sanofi Pasteur (unit of Sanofi- Aventis Group; France)

Licensing agreement for Oxford's T-SPOT technology for use in vaccine programs

T-SPOT offers an approved method for directly quantifying antigen-specific  T cells (4/4)


ProBioGen AG*

Minapharm (Egypt)

Agreements to develop two therapeutic proteins, one exclusively for Minapharm and a second for co-promotion

In the first deal, ProBioGen will apply its cell generation process for biopharmaceutical cell  lines and Minapharm will carry out the research and development, production and commercialization; the second deal calls for the companies to co-develop a second-generation product (4/19)



Boehringer Ingelheim Pharmaceuticals Inc.

Agreement in the field of protein crystallography

Proteros is entitled to research funding and success payments for the generation and analyses of protein-ligand structures of hits and evolved chemical entities from BI programs (5/15)


pSivida Ltd.
(Australia; PSDV)

Pfizer Inc.

Licensing deal to use sustained- release drug delivery, including pSivida's Medidur, in ophthalmic applications

Pfizer agreed to invest $5M in ordinary shares up front, proceeds of which will be held in escrow until pSivida uses them to redeem an outstanding convertible note; another $5M investment from Pfizer could come later and the rest of $165M would be paid in development and sales milestones (4/4)



Astellas Pharma (Japan)

Licensing agreement for Regeneron's VelocImmune antibody discovery technology

Astellas will pay Regeneron $120M over the next five years, including $20M up front, for a non-exclusive license for the technology; Regeneron also is entitled to a mid-single-digit percentage royalty (3/30)


Stem Cell
Innovations Inc.

Lundbeck A/S (Denmark)

Agreement to examine the hepatic metabolism of a set of compounds from Lundbeck

SCI will use its C3A human liver cell line, which was developed for use in an artificial liver used to support patients waiting for transplantation (5/7)


SuperGen Inc.

Intas Pharmaceuticals Ltd. (India)

Agreement for SuperGen to sell the rights to the anticancer agents mitomycin and paclitaxel

The sale price is $1.2M; SuperGen also will sell for additional consideration certain related inventory (4/20)



Bayer Schering  Pharma AG

Exclusive licensing  agreement to the oral, selective histone deacetylase inhibitor, MS-275

Bayer will receive up-front fees and milestone payments (4/13)



Novartis AG (Switzerland)

Exclusive, worldwide licensing agreement to  develop and commercialize rufinamide to treat mood disorders outside of Japan

Tokyo-based Eisai Co. Ltd. holds worldwide rights in Japan (4/23)


Transgene SA
(France; Eurolist: TNG)

F. Hoffmann-La Roche Ltd. (Switzerland)

Collaboration on Transgene's late-stage vaccine against human papillomavirus-related diseases, TG 4001 (MVA-HPV-IL2)

Roche gained worldwide rights in ex- change for €13M up front and another €10M for a near-term milestone, along with up to €195M in development and sales-based milestones; total deal is worth $293M (4/11)


Vernalis plc

Servier (France)

Joint, three-year oncology drug discovery collaboration involving an undisclosed target

Companies will use Vernalis' drug discovery platform on the target; Vernalis will receive an up-front payment and be entitled to a share in the downstream success of the product (5/17)





# The information in the chart does not cover agricultural agreements or those between biotech companies.


* Private companies are indicated with an asterisk; ** Denotes the date the item ran in BioWorld International.


Unless otherwise noted, stock symbols listed are on the Nasdaq market.


AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; CSE = Copenhagen Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SWX = Swiss Stock Exchange.